News

Rare Demyelinating Disorder Tied to MS Drug


 

Dr. Miller described the PML cases and subsequent suspension of the drug from marketing as “a great tragedy for the entire MS community. We certainly hope that after the dust has cleared, we will be able to find a way to safely bring this drug back to patients,” he said, but added, “that remains to be seen.”

The FDA's public health advisory regarding natalizumabcan be found at www.fda.gov/cder/drug/advisory/natalizumab.htmwww.elan.com

Pages

Recommended Reading

Organized Acute Stroke Care Flourishes in U.S. : American Stroke Association task force releases recommendations to implement stroke care systems.
MDedge Psychiatry
Pituitary Dysfunction May Occur After Brain Injury
MDedge Psychiatry
Mutation Linked to Some Cases of Parkinson's : Identifying gene raises ethical questions about its use in testing, given the lack of preventive therapy.
MDedge Psychiatry
Autism Increase Not a Result of Reclassification
MDedge Psychiatry
MRI Opens Thrombolysis Window After Stroke
MDedge Psychiatry
Genetic Variant Increases Risk of Late-Onset Alzheimer's
MDedge Psychiatry
Think Aspirin for Intracranial Arterial Stenosis
MDedge Psychiatry
Light Tx May Surpass Melatonin
MDedge Psychiatry
Cognitive Deficits Can Persist After Brain Injury
MDedge Psychiatry
ADHD or bipolar disorder? Age-specific manic symptoms are key
MDedge Psychiatry